Shandong Buchang Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Shandong Buchang Pharmaceuticals şirketinin toplam hissedar öz sermayesi CN¥10.8B ve toplam borcu CN¥3.8B olup, bu da borç-öz sermaye oranını 35.4% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CN¥20.1B ve CN¥9.3B dir. Shandong Buchang Pharmaceuticals 'in FAVÖK'ü CN¥571.9M faiz karşılama oranı 5.4 dur. Şirketin CN¥1.3B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

35.4%

Borç/özkaynak oranı

CN¥3.82b

Borç

Faiz karşılama oranı	5.4x
Nakit	CN¥1.31b
Eşitlik	CN¥10.80b
Toplam yükümlülükler	CN¥9.35b
Toplam varlıklar	CN¥20.15b

Son finansal sağlık güncellemeleri

Is Shandong Buchang Pharmaceuticals (SHSE:603858) Using Too Much Debt?

Jul 29

We Think Shandong Buchang Pharmaceuticals (SHSE:603858) Is Taking Some Risk With Its Debt

Feb 28

Recent updates

The Market Doesn't Like What It Sees From Shandong Buchang Pharmaceuticals Co., Ltd.'s (SHSE:603858) Revenues Yet

Aug 26

Is Shandong Buchang Pharmaceuticals (SHSE:603858) Using Too Much Debt?

Jul 29

Why Investors Shouldn't Be Surprised By Shandong Buchang Pharmaceuticals Co., Ltd.'s (SHSE:603858) Low P/S

Apr 27

We Think Shandong Buchang Pharmaceuticals (SHSE:603858) Is Taking Some Risk With Its Debt

Feb 28

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 603858 'nin kısa vadeli varlıkları ( CN¥7.6B ) kısa vadeli yükümlülüklerini ( CN¥6.1B ) aşıyor.

Uzun Vadeli Yükümlülükler: 603858 şirketinin kısa vadeli varlıkları ( CN¥7.6B ) uzun vadeli yükümlülüklerini ( CN¥3.3B ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 603858 'nin net borç/öz sermaye oranı ( 23.2% ) tatmin edici olarak değerlendirilmektedir.

Borcun Azaltılması: 603858 şirketinin borç/öz sermaye oranı son 5 yılda 19.5% seviyesinden 35.4% seviyesine yükseldi.

Borç Kapsamı: 603858 'nin borcu işletme nakit akışı ( 24% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: 603858 'in borcuna ilişkin faiz ödemeleri EBIT ( 5.4 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.

Shandong Buchang Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is Shandong Buchang Pharmaceuticals (SHSE:603858) Using Too Much Debt?

We Think Shandong Buchang Pharmaceuticals (SHSE:603858) Is Taking Some Risk With Its Debt

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.076 (vs CN¥0.16 in 3Q 2023)

Shandong Buchang Pharmaceuticals Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024

The Market Doesn't Like What It Sees From Shandong Buchang Pharmaceuticals Co., Ltd.'s (SHSE:603858) Revenues Yet

Dividend of CN¥0.13 announced

Is Shandong Buchang Pharmaceuticals (SHSE:603858) Using Too Much Debt?

Shandong Buchang Pharmaceuticals Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Shandong Buchang Pharmaceuticals Co., Ltd., Annual General Meeting, Jun 28, 2024

First quarter 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.41 in 1Q 2023)

Why Investors Shouldn't Be Surprised By Shandong Buchang Pharmaceuticals Co., Ltd.'s (SHSE:603858) Low P/S

Now 26% undervalued

Shandong Buchang Pharmaceuticals Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Now 22% undervalued

We Think Shandong Buchang Pharmaceuticals (SHSE:603858) Is Taking Some Risk With Its Debt

Now 23% undervalued after recent price drop

Shandong Buchang Pharmaceuticals Co., Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024

Shandong Buchang Pharmaceuticals Co., Ltd. (SHSE:603858) announces an Equity Buyback for CNY 360 million worth of its shares.

Third quarter 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.41 in 3Q 2022)

Haikou Xinyingyang Investment Partnership Enterprise (Limited Partnership) and Xi Chong agreed to acquire 14% stake in Buchang Health Industry (Zhejiang ) Co., Ltd. from Shandong Buchang Pharmaceuticals Co., Ltd. (SHSE:603858),Hu Cunchao, Li Hui, and Hu Cunchao for CNY 0.

Second quarter 2023 earnings released: EPS: CN¥0.26 (vs CN¥0.35 in 2Q 2022)

Full year 2022 earnings released: CN¥1.50 loss per share (vs CN¥1.17 profit in FY 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.41 (vs CN¥0.30 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.35 (vs CN¥0.49 in 2Q 2021)

Investor sentiment deteriorated over the past week

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.45 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.49 (vs CN¥0.54 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.37 (vs CN¥0.28 in 1Q 2020)

New 90-day low: CN¥21.37

New 90-day low: CN¥21.77

New 90-day low: CN¥23.46

New 90-day low: CN¥23.63

New 90-day low: CN¥24.21

Third quarter earnings released

Jointown Pharmaceutical Group Co., Ltd. (SHSE:600998) intends to acquire remaining 51% stake in Hubei Buchang Jiuzhoutong Pharmaceutical Co., Ltd. from Shandong Buchang Pharmaceuticals Co., Ltd. (SHSE:603858) for CNY 21.8 million.

New 90-day low: CN¥24.81

First half earnings released

First half earnings released

Shandong Buchang Pharmaceuticals Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin